Work

A phase I study of BAY 38-3441 given as a short infusion daily for five days every 3 weeks. a National Cancer Institute of Canada Clinical Trials Group Study

Year: 2001

Type: article

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(01)80750-4

Authors: L. Seymour, L. Siu, G. Batist, J. Cammisano, M. Maclean, L. McIntosh, O. Petrenciuc

Language: English

Topic: Cancer therapeutics and mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1999870759

FWCI: 0.116

Cites:

Cited by: 1

Related to: 10